LH

• Labcorp Holdings Inc. announced on August 28, 2026 that executive management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference.
• A live audio webcast will be available on Labcorp's Investor Relations website and archived for 180 days.
• The press release was furnished as Exhibit 99.1 to the Form 8-K filed under Item 7.01 Regulation FD Disclosure.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Labcorp Holdings Inc. announced an Investor Day scheduled for Thursday, September 10, 2026, from 9 a.m. to noon ET.
• A live webcast will be available on the Labcorp Investor Relations website, with a replay and supporting materials after the event.
• The announcement was made via a press release dated August 17, 2026, furnished as Exhibit 99.1 to the Form 8-K.
• The filing was made under Item 7.01 Regulation FD Disclosure, as the information is being furnished, not filed.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Brian J. Caveney, M.D., will become EVP and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, effective September 1, 2026.
• Caveney will oversee Early Development Research Laboratories and Central Laboratories businesses.
• Caveney previously served as EVP and President, Early Development Research Laboratories and Chief Medical and Scientific Officer.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• Diluted EPS rose 28.5% to $3.64; adjusted EPS rose 14.9% to $4.99.
• Full-year 2026 revenue growth guidance raised to 5.4%-6.3%; adjusted EPS guidance raised to $18.10-$18.55.
• Board approved a $1.0 billion increase in share repurchase authorization, bringing total to $1.4 billion.
• Q2 capital allocation included $225.7M in acquisitions, $353.8M in stock repurchases, and $58.7M in dividends.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• The dividend is payable on September 11, 2026, to stockholders of record as of the close of business on August 28, 2026.
• The announcement was made via a press release furnished as Exhibit 99.1 to the Form 8-K filed on July 10, 2026.
• The filing was made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• A conference call and webcast will be held at 9:00 a.m. ET on the same day to discuss the results.
• The earnings press release and financial information will be posted on the Labcorp Investor Relations website.
• A replay of the webcast will be available for one year starting about two hours after the live event.
• The disclosure was made under Item 7.01 Regulation FD, with the press release furnished as Exhibit 99.1.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Labcorp Holdings Inc. announced it will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET.
• An archived recording will be available approximately 24 hours after the session and accessible for 90 days.
• The press release was furnished as Exhibit 99.1 to the Form 8-K filed on May 27, 2026.
• The disclosure was made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• At Labcorp's 2026 Annual Meeting on May 21, 2026, shareholders elected all 11 director nominees to one-year terms expiring at the 2027 annual meeting.
• Shareholders approved, in a non-binding advisory vote, the compensation of named executive officers with 66,519,291 votes for and 3,735,777 against.
• Shareholders ratified Deloitte & Touche LLP as independent auditor for fiscal year 2026 with 76,291,589 votes for and 53,650 against.
• A quorum of 76,382,627 shares (out of 82,187,046 outstanding) was represented at the meeting, and results were certified by the Inspector of Elections.

5.07 Submission of Matters to a Vote of Security Holders